GENE ONLINE|News &
Xilio Therapeutics Prices Public Offering of 12 Million Shares at $3 Each
Xilio Therapeutics has announced the pricing of its underwritten public offering. The company plans to offer 12,000,000 shares of its common stock at a price of $3.00 per share. Additionally, Xilio is granting underwriters a 30-day option to purchase up to an additional 1,800,000 shares at the same price. The gross proceeds from this offering are expected to total approximately $36 million before deducting underwriting discounts and other expenses.
The offering is set to close on February 17, 2026, subject to customary closing conditions. Xilio intends to use the net proceeds for general corporate purposes, which may include research and development activities, clinical trials, manufacturing efforts, and working capital needs. J.P. Morgan Securities LLC and Cowen and Company LLC are acting as joint book-running managers for the offering.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: February 12, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Sono-Tek and Diamond Quanta Collaborate on Ultrasonic Coating for Engineered Diamond Applications
2026-03-17
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data for Highest Dose Cohort in Eosinophilic Esophagitis Trial
2026-03-17
Troilus Gold Corp. Signs MOU with Boliden for Long-Term Copper-Gold Concentrate Supply from Quebec Project
2026-03-17
POET Technologies and Lessengers Partner to Develop 1.6T 2×DR4 Optical Transceivers for AI Networks
2026-03-17
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
